Abstract Search

ea0098c15 | Clinical – Chemo/SSA/Biologics | NANETS2023

Phase II study of frontline maintenance rucaparib in combination with nivolumab in extensive stage small cell lung cancer

Chauhan Aman , Kolesar Jill , Yan Donglin , Hao Zhonglin , McGarry Ronald , Villano John , Zinner Ralph , Maskey Ashish , Miller Jordan , Mullett Timothy , Khurana Aman , Zhou Xitong , Gupta Garima , Flora Daniel , Darnell Colleen , O'Neil Richard , Kunos Charles , Anthony Lowell , Arnold Susanne

Background: Immune checkpoint inhibitor (ICI) maintenance therapy is the standard of care for frontline management of extensive-stage small cell lung cancer (ES SCLC). However, the overall survival benefit of the addition of ICI maintenance to frontline ES SCLC treatment is modest and further improvement is needed. We hypothesized that the addition of poly (ADP-ribose) polymerase inhibition to ICI maintenance therapy for patients with platinum-sensitive ES SCLC could improve t...

0 shares

ea0098c27 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

ETCTN 10388: A first in human Phase I Trial of Triapine and Lutetium Lu 177 DOTATATE in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Chauhan Aman , Arnold Susanne , Kolesar Jill , Carson William , Weiss Heidi , Yan Donglin , El Khouli Riham , Khurana Aman , Beumer Jan , Soares Heloisa , Mulcahy Mary , Halfdanarson Thorvardur , Li Daneng , Jacene Heather , Ivy Percy , Kohn Elise , Wright John , Rubinstein Larry , Kunos Charles , Anthony Lowell , Konda Bhavana

Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitization. ETCTN 10388 (NCT04234568) evaluated safety and efficacy of the combination of lutetium 177 DOTATATE, a beta-emitting radionuclide in combination with triapine, a ribonucleotide reductase (RNR) inhibitor. <p class="abstext"...

0 shares

ea0098c28 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Chauhan Aman , Kolesar Jill , Yan Donglin , Li Daneng , Khurana Aman , Edgar Carson William , Arnold Susanne M. , Gore Steven , Rubinstein Larry , Kohn Elise C. , Percy Ivy S. , Xiao Ying , Dewaraja Yuni , Soares Heloisa P. , Hendrik Beumer Jan , Konda Bhavana , Sukrithan Vineeth , Brian Anthony Lowell

Background: Radiolabeled somatostatin analogs provide a means of delivering targeted radiation with a high therapeutic index to NETs that express somatostatin receptors (SSTRs). We hypothesize that the addition of an effective radiation sensitizer could help improve the antitumor activity of Lutathera. Radiation is a potent inducer of DNA damage. The primary repair mechanism of radiation-induced double-stranded breaks (DSBs) is the nonhomologous end-joining (NHEJ) pathway, in ...

0 shares

Endocrine Abstracts

Phase II study of frontline maintenance rucaparib in combination with nivolumab in extensive stage small cell lung cancer

ETCTN 10388: A first in human Phase I Trial of Triapine and Lutetium Lu 177 DOTATATE in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

BiosciAbstracts